Engineered fluidic systems to understand lymphatic cancer metastasis

Cite as: Biomicrofluidics 14, 011502 (2020); doi: 10.1063/1.5133970
Submitted: 29 October 2019 · Accepted: 12 January 2020 · Published Online: 28 January 2020

Joshua D. Greenlee and Michael R. King

AFFILIATIONS
Department of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee 37235, USA

ABSTRACT
The majority of all cancers metastasize initially through the lymphatic system. Despite this, the mechanisms of lymphogenous metastasis remain poorly understood and understudied compared to hematogenous metastasis. Over the past few decades, microfluidic devices have been used to model pathophysiological processes and drug interactions in numerous contexts. These devices carry many advantages over traditional 2D in vitro systems, allowing for better replication of in vivo microenvironments. This review highlights prominent fluidic devices used to model the stages of cancer metastasis via the lymphatic system, specifically within lymphangiogenesis, vessel permeability, tumor cell chemotaxis, transendothelial migration, lymphatic circulation, and micrometastases within the lymph nodes. In addition, we present perspectives for the future roles that microfluidics might play within these settings and beyond.

INTRODUCTION: THE RISE OF MICROFLUIDICS
The discrepancies between scientific data gathered in vitro and in vivo vs clinical settings suggest that new models are warranted to recapitulate human pathophysiological processes. For years, there has existed a challenge in the field of bioengineering and drug discovery concerning the effectiveness of 2D cell cultures to model human physiology and drug interactions observed clinically. Two-dimensional static cultures remain the standard for cellular biology; yet, these models lack physiological relevance and have often proven ineffective as clinical predictors due to the dilute and ineffective recapitulation of the cellular microenvironment. While in vivo models remain necessary to assess drug interactions in the preclinical setting, the average success rate of translation from animal models to clinical cancer trials is less than 8%. Aside from being “lost in translation,” animal models raise ethical concerns and are problematic when using human cells due to host-immune cell interactions.

The combination of these shortcomings has pushed research into the direction of using 3D and microfluidic platforms to recapitulate the physical and chemical microenvironments seen in vivo, while providing the means to precisely control and visualize cellular interactions in a high-throughput manner. Microfluidics employs the use of small channels on the scale of tens to hundreds of micrometers in diameter to process minute fluid volumes. Their small size allows for limited cell numbers or reagents, which are often expensive or low in quantity. Furthermore, these devices can more accurately model in vivo architectures through integration of 3D extracellular matrix (ECM) components. The spatiotemporal control of these devices has allowed researchers to study specific cellular interactions in a more precise and controlled manner. Microfluidics is also advantageous as it can be fabricated to incorporate small working distances to allow for high-resolution, real-time imaging.

The usage of biologically compatible material substrates from molds allows for high-throughput production of devices and subsequent analysis. A large majority of microfluidic devices for biological application use soft lithography techniques, which include fabricating a master “stamp” from a photocurable polymer such as SU-8. This master can be used to imprint features into elastomeric materials, such as polydimethylsiloxane (PDMS), with high resolution. PDMS is widely used in microfluidics since it is easy to handle, can be purposed in diverse applications, is economically viable, ideal for imaging due to its optical properties, and, most importantly, is biologically inert. While the field of microfluidics has advanced tremendously in terms of applications, the versatility of replication molding with PDMS meant that new fabrication...
techniques have lagged behind. Other means of fabrication often require advanced equipment and are not economically feasible at a small scale for research purposes, use materials that do not translate well with biological applications, or lack the high-resolution capabilities inherent with soft lithography.17 However, certain applications may require more intricate fabrication techniques, such as micromachining, 3D printing, or dry etching. Table I illustrates the ubiquity of PDMS and photolithography in the field of microfluidic biomedical research.

Replication of tissue microenvironments within microfluidic devices allows the modeling of complex physiological process systems in “organ on a chip” devices.17–18 Meanwhile, the incorporation of multiple organs on a chip in one integrated device can be used for the scaling of “microHumans” to study complex anatomical interactions and systemic drug toxicity.17–18 Although initially intended to bridge the gaps between 2D in vitro studies and in vivo work, 3D fluidic models are evolving to study pathologies and drug interactions directly in patient-specific devices.2,19–23 These technological advances have made it possible to study specific diseases, including cancer within a microfluidic device.2,12,24–26 The applications for microfluidic devices are evolving and emerging in the field of cancer research, both from a biological perspective of understanding roles of immune and stromal cells to a translational perspective of investigating the efficacy of therapeutics in preclinical models.

THE ROLE OF LYMPHTHACS IN CANCER METASTASIS

Approximately 90% of all cancer related deaths are attributed to metastasis.27 Despite its high morbidity, cancer metastasis is a very inefficient process in which less than 0.1% of circulating tumor cells (CTCs) will actually go on to colonize and form macrometastases.28 The metastatic cascade is composed of several sequential steps, each of which selects for a specific cellular phenotype that is able to overcome inhospitable environments. First, cancer and stromal cells in the primary tumor secrete proangiogenic factors such as VEGF to promote tumor microvascular networks of both blood and lymphatic vessels. Tumor cells then undergo an epithelial to mesenchymal transition (EMT) that promotes cell motility through the loss of cell–cell adhesion proteins such as E-cadherin and β-catenin.29 Motile cells will then migrate and invade the basement membrane of the nearby vasculature through both physical (high intratumoral pressures) and chemical (chemokine gradients) cues.28 Cells may enter the hematogenous or lymphatic circulation via transendothelial migration (TEM) from the tissue parenchyma into nearby blood or lymphatic vessels, respectively.27 In the case of lymphatic invasation, tumor cells will drain into collecting lymphatic vessels, eventually emptying into the sentinel or “tumor draining lymph nodes” (TDLN).20 Successful migration to the sentinel lymph nodes provides cells with a direct route to systemic lymph nodes and the bloodstream via the thoracic duct and subclavian vein.31,32 Once in circulation, cells can undergo extravasation, followed by a mesenchymal to epithelial transition (MET) and colonization of distant organs.27 As suggested from Paget’s “seed and soil” hypothesis, tumor cells will have genetic and phenotypic advantages to promote seeding in specific organs over others.33,34 Just as a seed needs proper nutrients to grow, tumor cell proliferation and survival is highly dependent upon the microenvironment where CTC extravasation occurs. This sequential model of metastasis is well studied but has proven to be an oversimplification in many cancer models and in clinical observation.31,35

It is estimated that 80% of carcinomas and melanomas metastasize via lymphatics.30 Despite the fact that the majority of all human cancers metastasize initially via the lymphatic system, the mechanisms of lymphogenous metastasis remain poorly understood and understudied compared to that of hematogenous metastasis.31,36 There are many factors that help determine which metastatic route a cell will take.38 Typically, metastatic subpopulations will develop mutational burdens, which may be preferential for one mode over another. For instance, CCR7+ tumor cells will preferentially traffic toward CCL21 secreted by lymphatic endothelial cells (LECs), promoting initial metastasis through the lymphatic system. This signaling axis is typically used in CCR7+ dendritic cells (DCs) trafficking into lymph nodes, while T-cells expressing CCR7 follow gradients toward increasing CCL19 secreted within the thymus and lymph nodes.38 Additionally, CCL21 can be upregulated by VEGF-C/VEGFR-3 signaling, which has been shown to be highly expressed in primary tumors and tumor-derived lymphatic neovascularization.31 By harnessing these signaling mechanisms employed by immune cells to traffic toward LECs for antigen presentation, cancer cells experience directed migration toward the lymphatic circulation.31,38 Physical and mechanical forces have also been shown to play a role in lymphatic homing. High interstitial pressures within solid tumors promote interstitial flow (IF) toward the periphery of the tumor where lymphatic vessels are concentrated.39 Interstitial flow has been shown to promote vascular remodeling and even promote tumor cell invasion via autologous chemotaxis toward lymphatic vessels along the tumor periphery. Furthermore, secretion of specific prolymphangiogenic factors can favor lymphatics vs blood.34 For example, upregulated VEGF-C and VEGF-D secretion by cancer cells have been shown to induce preferential lymphatic metastasis via LEC VEGFR-2 and VEGFR-3, whereas blood endothelial cell (BEC) angiogenesis prefers VEGF-A/VEGFR-1 signaling.

Lymphatic capillaries lack pericytes and tight interendothelial junctions typically seen in blood vessels.31,40 The leaky nature of lymphatic vessels facilitates tumor cell invasation via transendothelial migration, promoting initial metastasis. Likewise, the lower fluid shear environment within lymphatic vessels (in the range of 0.4 dyne/cm² with surges between 4 and 12 dyne/cm²)41,42 compared to blood vasculature (upward of 30 dyne/cm² in arteries)43,44 increases the likelihood of cell survival in transit.31 Mounting evidence exists suggesting that lymphatics may also play a role in curbing antitumor immune responses.35 For example, initial lymphatic vessels formed as a result of tumor-induced lymphangiogenesis exhibit upregulated expression of the immune checkpoint ligand programmed cell death ligand 1 (PD-L1), which induces CD8+ T-cell anergy upon tumor associated antigen (TAA) presentation via MHC class 1.31,36,46 In addition, tumor-induced LECs have been shown to prevent dendritic cell maturation, increase T-cell tolerization, and inhibit proliferation of T-cells that have been stimulated by proinflammatory cytokines.36,47,48

Biomicrofluidics 14, 011502 (2020); doi: 10.1063/1.5133970
© Author(s) 2020
| Application                          | Device summary                                                                 | Substrate         | Fabrication method | Major finding                                                                 | Cell lines                                                                 | Year  | Reference   |
|-------------------------------------|---------------------------------------------------------------------------------|-------------------|--------------------|--------------------------------------------------------------------------------|----------------------------------------------------------------------------|-------|-------------|
| Lymphangiogenesis and LEC barrier function | Nine chamber radial flow device to model capillary morphogenesis under interstitial flow with applications in TME modeling | PDMS with fibrin gels | PMMA micromachining | Interstitial flow is vital for lymphatic morphogenesis, migration and proper molecular gradients in vitro | HMVEC (human dermal Microvascular endothelial cells) (lymphatic and blood), human dermal fibroblasts, B16-F10 (murine melanoma) | 2010  | 61          |
| Mimicking drainage function seen in lymphatic microvasculature | PDMS with fibrin gels | SU-8 photolithography | Drainage is required to preserve vascular stability and perfusion rates within fibrin scaffolds | HMVEC | 2013 | 64 and 65 |
| Microcirculation model featuring both blood and lymphatic vessels for the purpose of examining vascular permeability | PDMS/PET membrane with fibronectin | SU-8 photolithography | Vascular permeability in a coculture LEC and BEC system mimicked responses seen in vivo | HMVEC (lymphatic and blood) | 2015 | 66 and 67 |
| Mimicking LEC sprouting seen in vivo using physical and biochemical cues | PDMS with fibrin gels | SU-8 photolithography | Interstitial flow-initiated outgrowth of lymphatic sprouts toward upstream of the flow while suppressing downstream-directed sprouting | HMVEC (lymphatic), NHLF (normal human lung fibroblasts) | 2016 | 62          |
| Modeling lymphangiogenesis and angiogenesis simultaneously within tumor microenvironment | PDMS with collagen-fibrin gels | SU-8 photolithography | Mimicked simultaneous angiogenesis and lymphangiogenesis of the TME using interactions of tumor cells with cellular and noncellular components | HUVEC (human umbilical vein endothelial cells), HMVEC (lymphatic), primary fibroblasts, SKOV3 (human ovarian adenocarcinoma), MKN-74 (human stomach adenocarcinoma), and SW620 (human colorectal adenocarcinoma) | 2017  | 63          |
| LEC/tumor cell crosstalk | Chemotaxis of tumor cells toward lymphatics via CCR7 signaling within a modified Boyden chamber | Modified Boyden chamber with Matrigel | ... | Physiological levels of IF can enhance tumor cell migration in the direction of flow via CCR7 autocrine signaling | HMVEC (lymphatic), MCF10A (human breast epithelial), MCF7 (human breast adenocarcinoma) | 2007  | 76          |
| Application | Device summary | Substrate | Fabrication method | Major finding | Cell lines | Year | Reference |
|-------------|----------------|-----------|-------------------|---------------|------------|------|-----------|
| Modeling crosstalk between LECs and cancer cells via VEGF-C and CCR7 signaling in a modified Boyden chamber | Modified Boyden chamber with collagen I | ... | VEGF-C acts in an autocrine fashion to increase tumor invasiveness by increasing the proteolytic activity and motility of tumor cells | HEUVEC, HMVEC (lymphatic), MDA-MB-435S | ZR75-1 (human breast carcinoma), and MDA-MB-435 (human melanoma) | 2009 | 77 |
| Pressure gradient across collagen gels creates interstitial flow that influences tumor cell migration | PDMS with collagen I | SU-8 photolithography | Interstitial flow creates competing mechanisms of tumor migration downstream (CCR7 dependent) and upstream (CCR7 independent) | MDA-MB-231, MDA-MB-435 | PDMS with collagen IV | 2011 | 78 and 79 |
| Modeling extravascular migration of tumor cells along lymphatics via 3D confined cell migration | PDMS with collagen IV | SU-8 photolithography | Subpopulations of cells showed sustained migratory potential despite treatment with Taxol chemotherapeutics | MDA-MB 231, H1650 (lung adenocarcinoma), H446 Lung carcinoma, PC3 (prostate adenocarcinoma), LnCaP (prostate carcinoma), U-87MG (glioblastoma), HT-29 (colorectal adenocarcinoma) | IFN-DC migration and interactions with cancer cells within 3D tumor environments | 2013 | 83 |
| First ex vivo crosstalk system via secreted factors between lymph node and tumor samples | PDMS with collagen I | SU-8 photolithography | CXCR4/CCL12 axis guides IFN-DC toward apoptotic tumor cells for antigen uptake | Primary IFN-DCs (IFN-alpha Dendritic cells), SW620 | MDA-MB 231, H1650 (lung adenocarcinoma), H446 Lung carcinoma, PC3 (prostate adenocarcinoma), LnCaP (prostate carcinoma), U-87MG (glioblastoma), HT-29 (colorectal adenocarcinoma) | 2017 | 88 |
| Transendothelial migration | Microgaps force cell deformation to study effects on transmigration potential | PDMS with Matrigel | SU-8 photolithography | Extravasation potential was significantly affected by endothelial lining | HMVEC, HepG2 (hepatocellular carcinoma), HeLa (cervical adenocarcinoma), MDA-MB-435 | 2007 | 98 and 99 |
| Application | Device summary | Substrate | Fabrication method | Major finding | Cell lines | Year | Reference |
|-------------|----------------|-----------|--------------------|---------------|------------|------|-----------|
| Tumor cell interactions with endothelial cell barrier function | | PDMS with hydrogel | SU-8 photolithography | Macrophage-secreted TNF-α induces endothelium permeability and tumor cell intravasation | HT1080, MDA-MB-231, RAW264.7 (macrophages) | 2012 | 93 |
| Tumor cell interactions with artificial microvasculature under physiological shear | | PDMS with collagen I | Aluminum replication molding | Cancer cells show biased growth toward vessels but do not contact the endothelium for transendothelial migration | MDA-MB-231, HT-1080, HUVEC, HMVEC | 2014 | 94 |
| Perfusion metastasis chip with microposts allowing for endothelial cell monolayer formation for angiogenesis and intravasation | | PDMS with fibrinogen | SU-8 photolithography | TNF-α treated EC monolayers demonstrated increased permeability and subsequent intravasation | MDA-MB-231 | 2014 | 70 |
| Cancer cell transmigration under transmural and interstitial flow across LEC monolayers | Somoss Watershed XC11122 | High-resolution stereolithography | Luminal and transmural flow upregulate tumor cell transmigration, partially through LEC CCL21 upregulation | HMVEC (lymphatic), MDA-MB-231 | 2015 | 101 |
| Simple transwell device to study mechanisms of tumor cell TEM in LECs | Transwell plates | … | Lymphangiogenic peptide adrenomedullin facilitates TEM by promoting cancer cell binding to LECs and gap junction coupling | HMVEC (lymphatic), SK-MEL-2 (human melanoma), MCF7 | 2015 | 103 |
| Simple transwell device with interstitial flow to study leukocyte and cancer cell transmigration | Transwell plates | … | Cancer cells prefer basal to apical transmigration in LECs compared to BECs | MCF7, MDA-MB-231, HMVEC, mouse primary dermal lymphatic endothelial cells, SVEC4-10 (mouse endothelial) | 2017 | 102 |
| Microfluidic channels separated by porous membrane lined with primary endothelial cell monolayer | PDMS with collagen I | Replication molding | Cancer cells adhere to endothelium under flow, but transmigration was not observed | HMVEC, H838 (non-small cell lung cancer), SK-Mel-28 (human melanoma) | 2018 | 95 |
| Lymphatic circulating tumor cells | Flow chamber to study tumor cell behaviors under lymphatic shear conditions | Parallel plate laminar flow chamber coated with collagen | … | Colorectal cancer cells remained attached, proliferative and alive under lymphatic shear conditions | RKO (human colorectal carcinoma), HCT-8 (colorectal adenocarcinoma) | 2007 | 106 |
Despite the increasing evidence for the roles of lymphatics in promoting cancer progression and dissemination, there are innate characteristics of lymphatics that promote antitumor immunity. For instance, the presence of lymphatic networks at the primary tumor are important for TAA trafficking to immune cells to evoke a robust T-cell response. In addition, lymphatic vessel density in solid tumors strongly correlates with the quantity of infiltrating cytotoxic CD8+ T-cells, promoting “hot” vs “cold” tumors in patients. The involvement of lymphatics in cancer dissemination extends into the clinic. The presence of metastases in the sentinel lymph nodes of cancer patients is used as a basis for establishing tumor staging, predicting patient prognosis and formulating treatment strategies. Axillary and sentinel lymph node biopsies in melanoma and breast cancer patients have proven to be fundamental for assessing the aggressiveness and extent of disease. In fact, sentinel lymph node (LN) biopsies will often reveal metastatic spread before detection by traditional imaging modalities such as positron emission tomography/computed tomography (PET-CT) or before the presence of blood-borne CTCs. The clinical ramifications of this on the degree of lymphatic involvement in metastasis demonstrates the importance of the role of the lymphatic system in cancer.

The complex roles of lymphatics in metastatic progression are not yet fully understood. What is apparent, however, is that better understanding of the interplay between tumor cells, their microenvironment, and the lymphatic system during metastasis is vital to the discovery of new therapeutics to exploit tumor cell weaknesses. The tight control of physical and chemical stimuli, high-throughput nature, high-resolution capacity, and physiologically relevant architecture of microfluidics provide excellent means for better understanding these intricate interactions.

### MICROFLUIDIC MODELS OF LYMPHOGENOUS METASTASIS

#### Lymphangiogenesis and LEC barrier function

Lymphatic vasculature is comprised of initial lymphatic vessels and collecting vessels, which function to prevent the accumulation of fluid, termed edema, in tissues. Additionally, these vessels function to transport pathogens, antigens, and antigen-presenting cells (APCs) from tissues toward immune cells residing within the lymph nodes. Initial lymphatic vessels, also known as lymphatic capillaries, range from 35 to 70 μm in diameter and absorb interstitial fluids, facilitated by pressure gradients between the interstitium and vessel lumen. The lymph then drains into downstream collecting vessels where unidirectional valves and smooth muscle contractions facilitate transport into the draining lymph nodes. Lymphangiogenesis is the analog to angiogenesis, the process in which lymphatic endothelial cells sprout to create new vasculature off of existing vessels. Tumor-induced lymphangiogenesis is characterized by VEGF-C or VEGF-D overexpression in tumors, which has been correlated with an increase in lymph node metastasis and high morbidity in patients. Lymphatic vessels have a high permeability due to discontinuous interendothelial junctions and a sparse surrounding basement membrane.
facilitates immune cell intravasation and extravasation, it makes vessels susceptible to metastatic tumor cells as well.

Interstitial flow has been shown to be an important regulator of lymphangiogenesis in vitro and in vivo.\textsuperscript{59,60} To model this, the Swartz Lab created a multichambered, high-throughput flow device capable of replicating interstitial flow pressures through a 3D extracellular matrix.\textsuperscript{61} This PDMS device allowed live imaging of morphogenesis of lymphatic and blood endothelial cells while incorporating tumor microenvironment (TME) components with cocultures of tumor cells and fibroblasts. A related study by Kim \textit{et al.} also investigated the roles of IF on lymphangiogenesis, discovering directionality of lymphatic sprouting was flow dependent.\textsuperscript{62} Interstitial flow-induced upstream lymphatic sprouting and suppressed downstream sprouting via LEC polarization. This PDMS device consisted of a center 3D fibrin channel containing LECs and microposts, surrounded by two flow channels and a 3D fibroblast culture. The same group later adapted the design to study the complex networks of lymphatic vessels in coculture with BECs, fibroblasts, and cancer cells in a 3D tumor microenvironment model, as shown in Fig. 1(a).\textsuperscript{63} This is the only known study to mimic angiogenesis and lymphangiogenesis simultaneously in one 3D microfluidic platform.

Interstitial flow is also key in preserving endothelial barrier function in lymphatic neovasculature.\textsuperscript{39,60} A study by Wong \textit{et al.} used a new device to study endothelial cell perfusion to demonstrate the importance of lymphatic drainage in preserving vascular stability.\textsuperscript{64,65} This device in particular has the capability of being repurposed by introducing coculture with cancer cells to study endothelial cell permeability and transendothelial migration under lymphatic drainage conditions. More recently, a device by Sato \textit{et al.} investigated vascular permeability within cocultures of LECs and BECs.\textsuperscript{66} The PDMS device consisted of two microfluidic channels where LECs and BECs were cultured back-to-back, separated by a fibronectin coated polyethylene terephthalate (PET) membrane.\textsuperscript{67} Their findings demonstrated that physiological flow conditions enhanced cell–cell junctions and recapitulated microvascular architecture seen in vivo.\textsuperscript{66}

While angiogenesis is a well characterized process that has been incorporated into many microfluidic devices,\textsuperscript{68-73} the process of lymphangiogenesis is less well understood. The described microfluidic devices have demonstrated advances in understanding the roles of lymphatic vessel sprouting, morphogenesis, and permeability in the context of the tumor microenvironment. In particular, within the last few years there has been emphasis on the fabrication of lymph node micrometastases \textit{in vitro}.\textsuperscript{111}

### FIG. 1. Current microfluidic models to study the mechanisms of lymphatic cancer metastasis. Representative devices used to study (a) lymphangiogenesis [reproduced with permission from Chung \textit{et al.}, Adv. Healthcare Mater. \textbf{6}, 1700196 (2017). Copyright 2017 John Wiley and Sons], (b) crosstalk between LECs and tumor cells [reproduced with permission from Polacheck \textit{et al.}, Proc. Natl. Acad. Sci. U.S.A. \textbf{108}, 11115 (2011). Copyright 2011 National Academy of Sciences], (c) Transendothelial migration [reproduced with permission from Pisano \textit{et al.}, Integr. Biol. (Camb.) \textbf{7}, 525. Copyright 2015 Oxford University Press], (d) CTCs in lymphatic circulation [reproduced with permission from Chen \textit{et al.}, Sci. Rep. \textbf{5}, 9880 (2015); Copyright 2015 Author(s), licensed under a Creative Commons Attribution Springer Nature License], and (e) Formation of lymph node micrometastases [reproduced with permission from Chandrasekaran \textit{et al.}, Lab Chip \textbf{14}, 118 (2014). Copyright 2014 Royal Society of Chemistry].
of more complex systems that model lymphangiogenesis in parallel with angiogenesis. While multiple devices have been employed to study lymphatic microvasculature function, few have incorporated components to model lymphangiogenesis in the context of the tumor microenvironment. Modifying or reapplying these devices to represent tumor-induced vascular remodeling will be instrumental in the future. The field is mature from a device design standpoint, but there remain many opportunities within existing devices for further studies, especially regarding drug modulation of lymphangiogenesis and LEC barrier function. Currently, there are no FDA-approved compounds to prevent tumor-induced lymphangiogenesis, supporting the use of such microfluidic devices to study novel drug candidates before human trials.74

**Lymphatic-induced migration and tumor crosstalk**

The likelihood of successful metastatic dissemination is contingent upon a tumor cell’s migratory potential.75 Cancer cells in the primary tumor undergo EMT characterized by a loss of adhesion proteins like E-cadherin and the upregulation of vimentin.76,77 These cancer cells resemble a cancer stem cell phenotype and morphology, including a decrease in proliferation and increase in migratory capacity. As previously alluded to, these cancer cells are able to harness the same chemotactic mechanisms typically employed by immune cells to migrate toward and into initial lymphatics.78,79 Meanwhile, high intratumoral pressures direct interstitial flows toward the tumor periphery into peritumoral lymphatic vessels.39 High interstitial flows can cause fibroblast contraction and collagen fiber alignment, along with tumor stiffening. This will increase tumor invasiveness, as cells will more easily migrate through aligned collagen fibers. When taken together, all these mechanisms promote tumor cell migration away from the primary tumor and toward peritumoral vasculature.

The Swartz Lab has pioneered microfluidic modeling of tumor cell chemotaxis toward lymphatics. In one study, Shields et al. used a modified 3D Boyden chamber, consisting of a tumor cell culture in 3D ECM with LECs cultured on the underside of the chamber.75 By introducing interstitial flows of just 0.2 μm/s through the 3D ECM in the absence of LECs, cancer cell migration was enhanced via autologous CCR7 signaling. This novel finding first suggested that IF not only promoted directed migration through physical mechanisms but also through autocrine signaling where a chemotactic gradient naturally forms at the leading edge of the cell. When cultured with LECs, paracrine CCL21 secretion enhanced CCR7 signaling and offered a complementary role for lymphatic-directed chemotaxis. A separate study from the Swartz Lab built upon this observation in a similarly modified Boyden chamber device. Issa et al. demonstrated that tumor cell VEGF-C enhanced LEC CCL21 secretion through VEGFR-3 signaling, thereby enhancing tumor cell proteolysis and migration toward LECs.77

Polacheck et al. created a two-channel PDMS device separated by a collagen interface in which a pressure difference between channels drove interstitial flow through the device, as shown in Fig. 1(b).76,77 This study further supported the previously demonstrated phenomena of autologous CCR7 chemotaxis downstream of interstitial flow. However, when blocking CCR7 signaling, migration was directed upstream of flow, hypothesized to be linked to flow-induced tension in integrins via phosphorylation of focal adhesion kinase (FAK).

Tumor cells under confinement show preferential migration in paths of least resistance through trajectories created by leader cells, collagen fiber alignment, or on the periphery of preexisting lymphatic and blood vessels.85 Irimia and Toner created a high-throughput model of cancer cell migration under confinement using collagen-filled, cell-sized microchannels in 96 well plates.86 When treated with paclitaxel chemotherapy, overall cell migratory potential of MDA-MB-231 cells was significantly decreased. However, subpopulations of cells proved resistant to migratory inhibition and showed sustained migration in the presence of high concentrations of drug.

Tumor cells have been shown to create tolerization of immune cells prior to inhabiting the TDLN, creating a premetastatic niche that can be ideal for tumor cell seeding.87,88 Moreover, technological advancement in the way of ex vivo tissue cultures has enabled more translational studies of drug-tumor interactions and personalized medicine.89,90 Recently, Shim et al. created the first ex vivo crosstalk system via secreted factors between lymph node and tumor slices. They designed a multilayer PDMS device with integrated pumps to recirculate supernatant between tumor and LN tissue under physiological interstitial flow conditions.91 Their findings demonstrated that LN tissues cultured with tumor tissue contained immunosuppressed T-cell populations, as characterized by decreases in IFN-γ secretion, supporting established in vivo findings.

Since cancer cell and immune cell migration employ the use of the same chemokine signaling axes, it is important to understand how migration is modulated by the presence of drugs or immunotherapies. Parfaito et al. created a PDMS device with an immune chamber and tumor chamber separated by confined connecting chambers to demonstrate the mechanisms behind IFN-α-conditioned DC migration toward tumor cells.92 Their results demonstrated that the CXCR4/CCL12 axis guides dendritic cells toward apoptotic cancer cells leading to TAA phagocytosis and cross-presentation to naïve T-cells. This study focused on immune cell migration upon treatment of tumor cells, but the device could straightforwardly be repurposed to examine simultaneous immune cell and cancer cell-directed migration in the presence or absence of drugs.

Overall, this has been the most studied stage in lymphatic metastasis using microfluidics. Precise control over device characteristics such as collagen density (and consequential stiffness), flow profiles, pressure gradients, chemotactic gradients, and channel architectures make microfluidic devices well suited for modeling tumor migration and lymphatic crosstalk. However, to date, no device yet exists to study LEC-induced chemotaxis of cancer cells simultaneously in the presence of immune cells. Most current systems are binary, only comprised of cancer cell lines in culture with LECs, or in the case of the previously described device, only address mechanisms of immune cell trafficking. Modeling the roles of LEC directed migration with lymphatics and cancer cells in tandem will be important for understanding drug interactions to prevent off target effects on immune cells. Moreover, the addition of immune cells will provide insights into symbiotic relationships between immune cells and cancer cells during lymphatic-directed migration. Furthermore, the inclusion of other cell types such as cancer associated fibroblasts (CAFs) will be key in elucidating the
complex roles these cell types have during migration. More recent studies incorporating primary samples and ex vivo tissue samples are gaining traction due to their translational relevance. It is expected that this trend will continue, specifically with applications in personalized medicine. One could imagine the reapplication of the aforementioned Shim et al. ex vivo device, with patient derived slices of an excised tumor and LN samples to study patient immune tolerization and immunotherapy efficacy.

Transendothelial migration through lymphatic endothelium

A cancer cell’s ability to disseminate to other organs is fully dependent upon its ability to enter the lymphatic or hematogenous circulation. Intravasation is the process in which cancer cells invade the basement membrane of the vasculature and then enter the circulation through a process known as transendothelial migration (TEM). There are two modes of TEM: paracellular (through endothelial cell–cell junctions) or transcellular (through endothelial cell bodies). TEM in the context of cancer intravasation or extravasation has been studied in a range of microfluidic devices. However, until recently, these studies were carried out predominantly with BECs in the context of blood vessel intravasation and extravasation.

The Kamm lab created a successful device that set a precedent for the study of endothelial barrier function in the context of tumor metastasis. Their PDMS device consisted of two independent channels where endothelial cells and tumor cells were seeded, separated by a 3D ECM hydrogel region. Permeability of BEC monolayers cocultured with macrophages and subsequent transmigratory potential of HT1080 fibrosarcoma cells were quantified. This study was instrumental in elucidating the role of macrophage-secreted TNF-α in endothelial monolayer permeability and tumor intravasation potential. Building on this, another group created artificial microvasculature from cylindrical channels lined with endothelial cells to study cancer cell migration and intravasation into perfusable vessels. Another system was used to study extravasation, where a two-chamber PDMS device was split with a porous membrane containing an endothelial monolayer. Cancer cells were perfused through the top chamber, while the bottom chamber contained a reservoir to collect any extravasated cancer cells. While the cancer cells adhered to the endothelium, no transendothelial migration was observed within the short time frame of cell rolling. These are just some of the many current microfluidic platforms used to study cancer cell migration through the blood endothelium. Multiple devices have been created to study TEM through vascular endothelium in concert with other metastatic processes. Lee et al. created a “metastasis chip” that modeled both angiogenesis and subsequent intravasation of MDA-MB-231 cells together in one platform. Likewise, Chaw et al. created a multistep device where cells underwent deformation through 10 μm trenches before passing through an endothelial monolayer. The latter has applications in studying cell confinement through vessel constriction and subsequent lymphatic extravasation, an understudied phenomena.

More recently, microfluidic devices have been fabricated for the purpose of investigating the role of the lymphatic endothelium in TEM. Increasing emphasis on the role of lymphatics in initial metastasis along with the innate differences between blood and lymphatic endothelium has motivated such studies. For instance, unlike vascular endothelial monolayers, lymphatic monolayers are characterized by having increased permeability, an incomplete or absent basement membrane, and sparse, overlapping intercellular junctions. The Swartz Lab pioneered one of the first devices of cancer cell transmigration in LECs. They fabricated a five-channel microfluidic chamber that was designed to deliver both luminal and transmural flow to LEC monolayers, as shown in Fig. 1(c). Tumor cells in a 3D extracellular matrix were cultured above a membrane containing the monolayer. This device demonstrated that luminal, interstitial, and transmural flow promoted intravasation of MDA-MB-231 cells. The device was validated by demonstrating that luminal flow augmented LEC expressed CCL21 to drive cancer cell migration. Xiong et al. created a simplified version that used transwell inserts coated with an LEC monolayer to study vectorial migration and intravasation of immune cells and breast cancer cell lines. This more recent model was designed to be more readily accessible and easier to use for other research labs to study TEM. A similar system using transwell inserts was used by Karpinich and Caron to study tumor cell interaction with lymphatic endothelium. Their study demonstrated that the peptide adrenomedullin promotes coupling of cancer cells to LEC gap junctions and facilitates heterocellular communications to induce transendothelial migration.

Microfluidic platforms are excellent tools for studying transendothelial migration of cancer cells, largely due to the ease of visualization via live cell imaging. In addition, precise control of endothelial monolayers more closely mimics endothelial barrier function observed in vivo. Due to known differences between the lymphatic and blood endothelium, there exists a need to understand the different roles they play in relation to cancer cell intravasation. The majority of established hematogenous intravasation and extravasation devices could be readily modified to study LEC barrier function as well. Although straightforward in principle, inherent differences between blood and lymphatic endothelium will require these repurposed devices to be thoroughly screened and calibrated with LECs. If successfully implemented, future studies may examine differences in the transmigratory potential of cancer cells between BECs and LECs within the same device, potentially revealing subpopulations of phenotypes that are prone to lymphatic vs hematogenous TEM. In addition, cancer cell extravasation through lymphatics is poorly understood and few in vitro or in vivo models exist to study this phenomenon. Modifying existing extravasation devices by culturing LECs instead of BECs will allow for modeling cancer cell rolling, arrest within the lymph node, and extravasation from lymphatics into nearby or distal tissues.

Lymphatic circulating tumor cells

Once cancer cells transmigrate through the endothelium and enter the lymphatic circulation, they are subject to a unique physical and chemical environment. There are many differences in the rheology and flow dynamics between lymphogenous and hematogenous circulation. With the absence of red blood cells and platelets, the viscosity of lymph and interstitial fluid can be
two- to fourfold less than that of blood.\textsuperscript{104,105} Initial lymphatic vessels have a low Reynolds number flow within the Stokes flow regime, and in the largest vessels draining into the thoracic duct, the flow remains laminar.\textsuperscript{54} This deviates from arterial blood flow, which is mostly laminar but can become turbulent in larger arteries. Overall, the higher shear rates within the blood flow make CTC survival inauspicious compared to those within lymphatics.

Early efforts to model shear effects of lymphatics on metastatic tumor cells included the use of parallel plate flow chambers, as demonstrated in a previous study with colorectal cancer cell lines.\textsuperscript{31,32} In that study, a constant shear stress of 1.2 dyne/cm\textsuperscript{2} was applied to cancer cells while cell proliferation, spreading, and apoptosis were quantified. In two separate studies, our lab modeled dynamic shear on CTC's in human blood using a cone-and-plate viscometer.\textsuperscript{107,108} These studies demonstrated that physiological shear stress can sensitize cancer cells to TNF-\textalpha \textsuperscript{110} related apoptosis inducing ligand (TRAIL) via the activation of mechanosensitive ion channels.\textsuperscript{109} Similar to parallel plate flow chambers, a cone-and-plate viscometer is widely available, easy to use, and readily adaptable to model a variety of different physiological shear processes, making it suitable for studying cancer cells in lymphatic transit.

The lymphatic system utilizes both extrinsic and intrinsic phasic pumping mechanisms from the surrounding lymphatic muscle to produce the pulsatile flow of lymph from tissue.\textsuperscript{41,42,44} The contractile properties of the lymphatics can create confined architectures for cancer cells, augmenting cell motility, proliferation, and survival via the process of mechanotransduction.\textsuperscript{110} Chen et al. created a migration device with choke points ranging from 6 to 30 \textmu m to model metastasis through lymphatic capillaries.\textsuperscript{111} This PDMS device, as shown in Fig. 1(d), consisted of two separated serpentine channels, one loaded with cells and the other with chemotactic agents, separated by straight migration channels with constricted choke points of various diameters. Using MDA-MB-231 cells, cell migration through tight choke points was revealed to be dependent on Map Kinase family member p38\textgamma.

Despite the high concentrations of immune cells surrounding the lymphatics, cancer cells are often able to seed within the sentinel lymph nodes and form micrometastases.\textsuperscript{109} Small and clinically undetectable without a lymph node biopsy, these cancer cells can reside and remain senescent for years while evading immune detection. To mimic this, our group created a PDMS microcavity device that recapitulated the architecture of the lymph node, as shown in Fig. 1(e).\textsuperscript{112} The device was fabricated using deep reactive ion etching in silicon, followed by gas expansion molding in PDMS to create spherical microbubbles.\textsuperscript{113} Natural killer cells were cocultured with cancer cells, modeling interactions between micrometastases, immune cells, and therapeutics. Although this study was only conducted under static conditions, the same device was used in a separate study under a continuously perfused flow to culture 3D spheroids.\textsuperscript{114}

Currently, there exist flow devices that can be applied to the study of lymphatic and hemodynamic shear on migratory cancer cells. Both parallel plate flow chambers and cone-and-plate viscometers are easily adaptable and widely available devices to study such phenomena. Despite this, surprisingly few studies exist to study cancer cell transit in lymphatic circulation. This represents an important research opportunity to make these devices more physiologically relevant. This may include culturing LEC monolayers on the inner walls of a device while perfusing intraluminal lymphatic flow to CTCs. Furthermore, the creation of a device that allows for vessel dilation and constriction via smooth muscle, or artificially via transmural pressure, would better replicate the lymphatic behavior experienced \textit{in vivo}. These physiological conditions may be modeled after similar devices that use whole artery or vein segments \textit{ex vivo}.\textsuperscript{115,116} Meanwhile, there is a need for more devices to model cancer cell seeding and senescence within the tumor draining lymph nodes, specifically devices that incorporate immune cell interactions with cancer cells. There currently are multiple “lymph node on a chip” devices existing outside of the applications of cancer.\textsuperscript{117–119} Although outside of the scope of this review, incorporating cancer cells within lymph node on chip microenvironments may elucidate the mechanisms behind cancer cell seeding and survival.

CONCLUSIONS AND FUTURE PERSPECTIVES

Despite their great potential and versatility, microfluidic devices have not been fully harnessed to study the intricacies of lymphogenous metastasis. While there are an abundance of microfluidic devices studying metastasis in the context of the bloodstream, few devices exist that incorporate lymphatics as part of or the focus of their model. This is surprising since the majority of all cancers metastasize via lymphatics and the mechanisms of lymphogenous metastasis are in many ways as poorly understood as that of hematogenous metastasis.\textsuperscript{30} Given that the infrastructure of the aforementioned devices are widely adaptable, we propose that progress within the field will mostly come from new applications of previously developed systems. A germane initial step would be to recreate previous studies, such as those modeling angiogenesis or TEM into the blood vessels but replacing blood microvasculature with lymphatic microvasculature. Even more ideal would be the incorporation of blood vessels and lymphatics within the same device, similar to that described by Sato et al.\textsuperscript{66} This could be instrumental in elucidating how cells differentiate between lymphogenous vs hematogenous metastasis, while characterizing subpopulations that are predisposed to one mode over another. Moreover, combining multiple stages within one device, as done by Lee et al., who studied both angiogenesis and intravasation,\textsuperscript{70} will be useful to determine how different metastatic steps affect one another. Fabrication of these all-in-one "lymphatic metastasis on a chip" devices will advance the field toward a device capable of modeling the entire metastatic cascade within one platform.

As previously mentioned, there may be difficulties with replacing BECs with LECs in existing devices. Although both are endothelial cells and carry out similar functions, they have distinct transcriptional profiles, which make them unique in culture.\textsuperscript{120} For example, BECs appear to be more reliant on ECM interactions for proper functionality, indicating that ECM components in existing devices with endothelial monolayers may need to be tailored to suit LEC culture. Additionally, lymphatic endothelium is known to have relatively looser interendothelial junctions, which could pose challenges for culturing uniform monolayers within devices.\textsuperscript{112,122} Incorporating LECs into existing devices will require careful
observation and calibration to ensure physiological relevance, especially when adapting features such as flow profiles, cell densities, and ECM concentrations.

Immune cells play complex roles in relation to cancer development, and as such, numerous microfluidic devices exist to study these interactions. Surprisingly, these devices tend to look exclusively at cancer-immune cell interactions strictly within the tumor microenvironment, not in relation to their roles during metastasis. Cancer cells trafficking toward and into the lymph nodes are likely to interact in some capacity with both adaptive and innate immune cells, further warranting their inclusion within these microfluidic systems. Investigating the roles of the immune system will be key to not only understanding how cancer cells can leverage these interactions but also for exploiting cancer cell weaknesses with immunotherapies.

For more translational studies to exist, microfluidic devices must become more user-friendly and compatible for use in the clinical setting. This includes the integration of automated image processing, routine sample processing, and minimalization of complex system components to allow for the analysis to be carried out to completion within hospital laboratories. Meanwhile, reproducibility of such devices will be necessary for widespread implementation. The first step in the inclusion of clinical microfluidic devices would be validating drug toxicology and biological phenomena observed in vivo and in humans. This includes examining drug interactions of approved FDA compounds that have extensive clinical data and comparing those same interactions within relevant microfluidic devices for validation purposes. With regard to lymphatic devices, testing an FDA-approved compound such as sorafenib, which has been shown to interfere with LEC expressed VEGFR-2 and VEGFR-3 and has been approved for the treatment of metastatic renal cell carcinoma, within a lymphangiogenesis device would be applicable for validating modeling capabilities. In addition, testing well characterized checkpoint inhibitors such as PD-L1 targeting antibody atezolizumab to demonstrate blockage of checkpoint signaling by LECs would provide insights into the mechanisms behind an LEC targeted therapy. Interdisciplinary work within this field will be crucial for improved biological modeling and drug discovery.

ACKNOWLEDGMENTS

This work was supported by the National Institutes of Health (NIH) (Grant No. R01CA203991).

REFERENCES

1. M. Shang, R. H. Soon, C. T. Lim, B. L. Khoo, and J. Han, “Microfluidic modeling of the tumor microenvironment for anti-cancer drug development,” Lab Chip 19, 369–386 (2019).

2. A. Boussommer-Callego, R. Li, M. B. Chen, S. C. Wong, and R. D. Kamm, “Microfluidics: A new tool for modeling cancer-immune interactions,” Trends Cancer 2, 6–19 (2016).

3. Y.-H. V. Ma, K. Middleton, L. You, and Y. Sun, “A review of microfluidic approaches for investigating cancer extravasation during metastasis,” Microsyst. Nanoeng. 4, 17104 (2018).

4. J. Hoarau-Véchot, A. Rafii, C. Touboul, and J. Pasquier, “Halfway between 2D and animal models: Are 3D cultures the ideal tool to study cancer-microenvironment interactions?,” Int. J. Mol. Sci. 19, 181 (2018).

5. O. Candini et al., “A novel 3D in vitro platform for pre-clinical investigations in drug testing, gene therapy, and immuno-oncology,” Sci. Rep. 9, 1–12 (2019).

6. I. W. Mak, N. Evaniew, and M. Ghert, “Lost in translation: Animal models and clinical trials in cancer treatment,” Am. J. Transl. Res. 6, 114–118 (2014).

7. T. M. Whitesides, “The origins and the future of microfluidics,” Nature 442, 368–373 (2006).

8. J. F. Slaets, H. Elsami Amirabadi, P. Nair, C. M. Sahlgren, and J. M. J. den Toonder, “Metastasis in context: Modeling the tumor microenvironment with cancer-on-a-chip approaches,” Dis. Model. Mech. 11, dmm03100 (2018).

9. B. K. Gale et al., “A review of current methods in microfluidic device fabrication and future commercialization prospects,” Inventions 3, 60 (2018).

10. Y. A. Jodat et al., “On chip porous polymer membranes for integration of gastrointestinal tract epithelium with microfluidic ‘body-on-a-chip’ devices,” J. Microelectromech. Syst. 24, 5486 (2015).

11. W. Zhang, W. Y. Lee, D. S. Siegel, P. Tolias, and J. Zilberberg, “Patient-specific 3D microfluidic tissue model for multiple myeloma,” Tissue Eng. Part C Methods 20, 663–670 (2014).

12. H. Kimura, Y. Sakai, and T. Fujii, “Organ/body-on-a-chip based on microfluidic technology for drug discovery,” Drug Metab. Pharmacokinet. 33, 43–48 (2018).

13. Y. A. Jodat et al., “Human-derived organ-on-a-chip for personalized drug development,” Curr. Pharm. Des. 24, 5471–5486 (2018).

14. S. N. Bhata and D. E. Ingber, “Microfluidic organs-on-chips,” Nat. Biotechnol. 32, 760–772 (2014).

15. Y. A. Jodat et al., “Organ-on-chip models of cancer metastasis for future personalized medicine: From chip to the patient,” Biomaterials 149, 98–115 (2017).

16. A. Sontheimer-Pelps, B. A. Hassell, and D. E. Ingber, “Modelling cancer in microfluidic human organs-on-chips,” Nat. Rev. Cancer 19, 65–81 (2019).

17. H.-F. Tsai, A. Trubelja, A. Q. Shen, and G. Bao, “Tumour-on-a-chip: Microfluidic models of tumour morphology, growth and microenvironment,” J. R. Soc. Interface 14, 20170137 (2017).

18. W. Zhang, W. Y. Lee, D. S. Siegel, P. Tolias, and J. Zilberberg, “Patient-specific 3D microfluidic tissue model for multiple myeloma,” Tissue Eng. Part C Methods 20, 663–670 (2014).

19. P. Song, R. Hu, D. J. H. Tng, and K.-F. Yong, “Moving towards individualized medicine with microfluidics technology,” RSC Adv. 4, 11499–11511 (2014).

20. A. Williamson, S. Singh, U. Fernekorn, and A. Schober, “The future of the patient-specific body-on-a-chip,” Lab Chip 13, 3473–3480 (2013).

21. D. Caballero et al., “Organ-on-chip models of cancer metastasis for future personalized medicine,” J. R. Soc. Interface 14, 20170137 (2017).

22. J. R. Soc. Interface 14, 20170137 (2017).

23. W. Zhang, W. Y. Lee, D. S. Siegel, P. Tolias, and J. Zilberberg, “Patient-specific 3D microfluidic tissue model for multiple myeloma,” Tissue Eng. Part C Methods 20, 663–670 (2014).

24. P. Song, R. Hu, D. J. H. Tng, and K.-F. Yong, “Moving towards individualized medicine with microfluidics technology,” RSC Adv. 4, 11499–11511 (2014).

25. A. Jodat et al., “Human-derived organ-on-a-chip for personalized drug development,” Curr. Pharm. Des. 24, 5471–5486 (2018).

26. A. Williamson, S. Singh, U. Fernekorn, and A. Schober, “The future of the patient-specific body-on-a-chip,” Lab Chip 13, 3473–3480 (2013).

27. D. Caballero et al., “Organ-on-chip models of cancer metastasis for future personalized medicine: From chip to the patient,” Biomaterials 149, 98–115 (2017).

28. A. Sontheimer-Pelps, B. A. Hassell, and D. E. Ingber, “Modelling cancer in microfluidic human organs-on-chips,” Nat. Rev. Cancer 19, 65–81 (2019).

29. H.-F. Tsai, A. Trubelja, A. Q. Shen, and G. Bao, “Tumour-on-a-chip: Microfluidic models of tumour morphology, growth and microenvironment,” J. R. Soc. Interface 14, 20170137 (2017).

30. C. Chen, D. Gao, Y. Wang, S. Lin, and Y. Jiang, “A novel 3D breast-cancer-on-chip platform for therapeutic evaluation of drug delivery systems,” Anal. Chim. Acta 1036, 97–106 (2018).

31. T. M. Whitesides, “The origins and the future of microfluidics,” Nature 442, 368–373 (2006).

32. M. Shang, R. H. Soon, C. T. Lim, B. L. Khoo, and J. Han, “Microfluidic modeling of the tumor microenvironment for anti-cancer drug development,” Lab Chip 19, 369–386 (2019).
Biomicrofluidics

28. Valastyan and R. A. Weinberg, “Tumor metastasis: Molecular insights and evolving paradigms,” Cell 147, 275–292 (2011).
29. J. Brabletz, R. Kalluri, M. A. Nieto, and R. A. Weinberg, “EMT in cancer,” Nat. Rev. Cancer 18, 128–134 (2018).
30. S. Chandrasekaran and M. R. King, "Microenvironment of tumor-draining lymph nodes: Opportunities for liposome-based targeted therapy," J. Mol. Sci. 15, 20209–20339 (2014).
31. R. H. Farnsworth, M. G. Achen, and S. A. Stacker, “The evolving role of lymphatics in cancer metastasis,” Curr. Opin. Immunol. 53, 64–73 (2018).
32. R. Paduch, “The role of lymphangiogenesis and angiogenesis in tumor metastasis,” Cell. Oncol. 39, 397–410 (2016).
33. J. Filidder, “The pathogenesis of cancer metastasis: The seed and soil hypothesis revisited,” Nat. Rev. Cancer 3, 453–458 (2003).
34. Paget, “The distribution of secondary growths in cancer of the breast,” Lancet 133, 571–573 (1889).
35. D. Nathanson, “Insights into the mechanisms of lymph node metastasis,” Cancer 98, 413–423 (2003).
36. Podgrinska and M. Skobe, “Role of lymphatic vasculature in regional and distant metastasis,” Microvasc. Res. 95, 46–52 (2014).
37. Y. Wong and R. O. Hynes, “Lymphatic or hematogenous dissemination: How does a metastatic tumor cell decide?” Cell Cycle 5, 812–817 (2006).
38. V. Stein and C. Nombela-Arrieta, “Chemokine control of lymphocyte trafficking: A general overview,” ImmunoL 116, 1–12 (2005).
39. M. A. Swartz and A. W. Lund, “Lymphatic and interstitial flow in the tumour microenvironment: Linking mechanobiology with immunity,” Nat. Rev. Cancer 12, 210–219 (2012).
40. C. Scavelli et al., “Lymphatics at the crossroads of angiogenesis and lymphangiogenesis,” J. Anat. 204, 433–449 (2004).
41. T. C. Zawieja, “Contraction physiology of lymphatics,” Lymphat. Res. Biol. 7, 87–96 (2009).
42. B. Dixon et al., “Lymph flow, shear stress, and lymphocyte velocity in rat mesenteric prenodal lymphatics,” Microcirculation 13, 597–610 (2006).
43. G. P. Papaioannou and C. Stefanadis, “Vascular wall shear stress: Basic principles and methods,” Hellenic J. Cardiol. 46, 9–15 (2005).
44. N. Huang et al., “Fluid shear stress and tumor immunity,” Am. J. Cancer Res. 8, 763–777 (2018).
45. G. Garnier, A.-O. Glouetidt, and S. Hugues, “Tumor-associated lymphatic vessel features and immunomodulatory functions,” Front. Immunol. 10, 720 (2019).
46. E. F. Tewalt et al., “Lymphatic endothelial cells induce tolerance via PD-L1 and lack of costimulation leading to high-level PD-1 expression on CD8 T-cells,” Blood 120, 4772–4782 (2012).
47. E. F. Tewalt, J. N. Cohen, S. J. Rouhani, and V. H. Engelhard, “Lymphatic endothelial cells—key players in regulation of tolerance and immunity,” Front. Immunol. 3, 305 (2012).
48. S. Podgrinska et al., “Inflamed lymphatic endothelium suppresses dendritic cell maturation and function via Mac-1/ICAM-1-dependent mechanism,” J. Immunol. 183, 1767–1779 (2009).
49. N. Bordry et al., “Lymphatic vessel density is associated with CD8+ T cell infiltration and immunosuppressive factors in human melanoma,” ClinImmunology 7, e1162878 (2018).
50. M. Fankhauser et al., “Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma,” Sci. Transl. Med. 9, eaal4712 (2017).
51. S. Zaho et al., “Sentinel lymph node biopsy in breast cancer: A clinical review and update,” J. Breast Cancer 20, 217–227 (2017).
52. U. Veronese et al., “Sentinel-lymph-node biopsy as a staging procedure in breast cancer: Update of a randomised controlled study,” Lancet Oncol. 7, 983–990 (2006).
53. A. Gonzalez, “Sentinel lymph node biopsy: Past and present implications for the management of cutaneous melanoma with nodal metastasis,” Am. J. Clin. Dermatol. 19, 24–30 (2018).
54. E. Moore and C. D. Bertram, “Lymphatic system flows,” Annu. Rev. Fluid Mech. 50, 459–482 (2018).
55. W. Breslin, “Mechanical forces and lymphatic transport,” Microvasc. Res. 0, 46–54 (2014).
56. A. Christiansen and M. Detmar, “Lymphangiogenesis and cancer,” Genes Cancer 2, 1146–1158 (2011).
57. A. Stackar et al., “VEGF-D promotes the metastatic spread of tumor cells via the lymphatics,” Nat. Med. 7, 186–191 (2001).
58. J. Mandriota et al., “Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumor metastasis,” EMBO J. 20, 672–682 (2001).
59. Goldman et al., “Regulation of lymphatic capillary regeneration by interstitial flow in skin,” Am. J. Physiol. Heart Circ. Physiol. 292, H2176–H2183 (2007).
60. K. C. Boardman and M. A. Swartz, “Interstitial flow as a guide for lymphangiogenesis,” Circ. Res. 92, 801–808 (2003).
61. C. Bonvin, J. Overney, A. C. Sheib, J. B. Dixon, and M. A. Swartz, “A multi-chamber fluidic device for 3D cultures under interstitial flow with live imaging: Development, characterization, and applications,” Biotechnol. Bioeng. 105, 982–991 (2010).
62. S. Kim, M. Chung, and N. L. Jeon, “Three-dimensional biomimetic model to reconstitute sprouting lymphangiogenesis in vitro,” Biomaterials 78, 115–128 (2016).
63. M. Chung, J. Ahn, K. Son, S. Kim, and N. L. Jeon, “Biomimetic model of tumor microenvironment on microfluidic platform,” Adv. Healthc. Mater. 6, 1700196 (2017).
64. K. H. K. Wong, J. G. Truslow, A. H. Khankhel, K. L. S. Chan, and J. Tien, “Artificial lymphatic drainage systems for vascularized microfluidic scaffolds,” J. Biomed. Mater. Res. A 101A, 2181–2190 (2013).
65. G. M. Price and J. Tien, “Subtractive methods for forming microfluidic gels of extracellular matrix proteins,” in Microdevices in Biology and Engineering (Artech House, 2019).
66. S. Satoh et al., “Microcirculation-on-a-chip: A microfluidic platform for assaying blood- and lymphatic-vesSEL permeability,” PLoS ONE 10, e0137301 (2015).
67. B. Chueh et al., “Leakage-free bonding of porous membranes into layered microfluidic array systems,” Anal. Chem. 79, 3504–3508 (2007).
68. S. J. Jeong et al., “Sprouting angiogenesis under a chemical gradient regulated by interactions with an endothelial monolayer in a microfluidic platform,” Anal. Chem. 83, 8454–8459 (2011).
69. T. Xiaozhen et al., “A novel in vitro angiogenesis model based on a microfluidic device,” Chin. Sci. Bull. 56, 3301–3309 (2011).
70. H. Lee, W. Park, H. Ryu, and N. L. Jeon, “A microfluidic platform for quantitative analysis of cancer angiogenesis and intravasation,” Biomicrofluidics 8, 041502 (2014).
71. X. Wang, Q. Sun, and J. Pei, “Microfluidic-based 3D engineered microvascular networks and their applications in vascularized microtumor models,” Micromachines 9, 493 (2018).
72. N. Kuzmic, T. Moore, D. Devadas, and E. W. K. Young, “Modeling of endothelial cell migration and angiogenesis in microfluidic cell culture systems,” Biomech. Model. Mechanobiol. 18, 717–731 (2019).
73. D.-H. T. Nguyen et al., “Biomimetic model to reconstitute angiogenic sprouting morphogenesis in vitro,” Proc. Natl. Acad. Sci. U.S.A. 110, 6712–6717 (2013).
74. M. Yamakawa et al., “Potential lymphangiogenesis therapies: Learning from current anti-angiogenesis therapies—A review,” Med. Res. Rev. 38, 1769–1798 (2018).
75. C. D. Paul, P. Mistriotis, and K. Konstantopoulos, “Cancer cell motility: Lessons from migration in confined spaces,” Nat. Rev. Cancer 17, 131–140 (2017).
76. J. D. Shields et al., “Autoologous chemotaxis as a mechanism of tumor cell homing to lymphatics via interstitial flow and autocrine CCR7 signaling,” Cancer Cell 11, 526–538 (2007).
77. A. Issa, T. X. Le, A. N. Shoushtari, J. D. Shields, and M. A. Swartz, “Vascular endothelial growth factor-C and C-C chemokine receptor 7 in tumor cell-lymphatic cross-talk promote invasive phenotype,” Cancer Res. 69, 349–357 (2009).
cells, by tracking dendritic cell behaviour toward tumor cells, Application to tumor build and secure the tumor microenvironment, 116 implementation of a novel multi parameter control microfluidic platform for (IEEE, 2010), pp. 1 vivo tissue models in microfluidic systems, 1173 Two-way communication between ex vivo tissues on a microfluidic chip: R. Sudo et al., ”Micrometric control over the lymphatic and vascular network: toward a dynamic and multifunctional organoid model,” J. P. Sleeman et al., Microfluidic device to study cell transmigration under physiological shear stress conditions, T. Liu, L. Zhou, D. Li, T. Andl, and Y. Zhang, Live-cell imaging of invasion and intravasation, Cancer Res. 16074 (2002). S. Parlato et al., Microfluidic device for studying cancer metastasis, Lab Chip 1041–1047 (2013). M. Pisano, V. Triacca, K. A. Barbee, and M. A. Swartz, ”An in vitro model of the tumor-lymphatic microenvironment with simultaneous transendothelial and luminal flows reveals mechanisms of flow enhanced invasion,” Integr. Biol. (Camb.) 7, 525–533 (2015).